A driver parked his taxi to take a break in SoHo. He died behind the wheel. Then, for nearly a day, New Yorkers went about their lives — just feet from his body.
NYS Entity Status
NYS Filing Date
APRIL 04, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - ESSENTIAL ENVIRONMENTAL TECHNOLOGIES INC.
AROUND THE WEB
- For 18 Hours, Cabbie Sat Dead in Front Seat
By KIM BARKER - Monday Aug 14, 2017
- What is IoT’s disruptive role in the rise of sustaintech?
By Don Ye - Tuesday Aug 1, 2017
Environmental technology is breaking out of its shell and transforming into what is becoming today’s new buzzword: sustaintech, a combination of cleantech and smarttech. What does the emergence of sustaintech mean? It signals that we are witnessing how disruptive innovations are breaking down the long-standing status quo of sustainability originating from the cleantech sector. Essentially, the crossing point between sustainability and IoT is bringing disruptive technologies to the table, and this new megatrend is turning both investors’ and entrepreneurs’ heads. The...Read More
- A Slump in Tech Stocks That Leaves Some Investors Mystified
By LANDON THOMAS Jr. - Monday Jun 12, 2017
Shares of Netflix, Apple and other giant technology companies that have powered a market rally have taken an uncharacteristic pause.
- Amazon and Tencent Back Smartphone Maker Essential
Wednesday Aug 9, 2017
The startup founded by Google Android’s creator has raised $300 million in funding.
- Abbvie’s hep C drug pricing threatens Gilead’s dominance
By Max Nisen - Tuesday Aug 8, 2017
Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.
- Pittsburgh Gets a Tech Makeover
By STEVEN KURUTZ - Saturday Jul 22, 2017
The city is newly stylish, with hyped restaurants and an Ace hotel, thanks to a steady flow of Carnegie Mellon grads who decided to stay.